Kafi Hamidreza, Salamzadeh Jamshid, Beladimoghadam Nahid, Sistanizad Mohammad, Kouchek Mehran
Department of Clinical Pharmacy, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Neurology, Imam Hossein Medical and Educational Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran J Pharm Res. 2014 Spring;13(2):591-8.
Ischemic stroke is amongst the top four causes of mortality and the leading cause of disability in the world. The aim of this study was to evaluate the efficacy of a high dose memantine on neurological function of patients with ischemic stroke. In a randomized, 2 armed, open-label study, patients with mild to moderate cerebral thromboembolic event (CTEE) who admitted to Imam Hossein Hospital, Tehran, Iran, during preceding 24 hours, entered the study. Patients allocated in two study groups of memantine (as add-on therapy) and control. All patients were managed based on the American Heart Association and American Stroke Association (AHA/ASA) guidelines. Patients in memantine group received conventional treatment plus memantine 20 mg TID. The National Institute of Health Stroke Scale (NIHSS) was determined and recorded daily. The primary objective was comparison of the changes in NIHSS in the study groups at day 1 and day 5 of intervention. Significance level of p<0.05 was considered for statistical analysis. Patients were randomly allocated in control (15 women and 14 men, age 70.78 ± 10.92 years) and memantine (16 women and 8 men, age 73.33 ± 9.35 years) groups. There were no significant differences in age and sex distribution of two study groups as well as in comorbidities and concurrent drugs. NIHSS changes were significantly different between control (1.24 ± 0.96) and memantine group (2.96 ± 0.1), (p < 0.0001). Our results reveal that memantine added to standard treatment of CTEE could result in a remarkable decrease in the NIHSS confirming improvement of the neurological function of the patients.
缺血性中风是全球四大死因之一，也是导致残疾的主要原因。本研究旨在评估高剂量美金刚对缺血性中风患者神经功能的疗效。在一项随机、双组、开放标签研究中，前24小时内入住伊朗德黑兰伊玛目侯赛因医院的轻度至中度脑栓塞事件（CTEE）患者进入研究。患者被分配到美金刚（作为附加治疗）和对照组两个研究组。所有患者均按照美国心脏协会和美国中风协会（AHA/ASA）指南进行管理。美金刚组患者接受常规治疗加美金刚20mg每日三次。每天测定并记录美国国立卫生研究院卒中量表（NIHSS）。主要目标是比较干预第1天和第5天研究组中NIHSS的变化。统计分析的显著性水平为p<0.05。患者被随机分配到对照组（15名女性和14名男性，年龄70.78±10.92岁）和美金刚组（16名女性和8名男性，年龄73.33±9.35岁）。两个研究组在年龄、性别分布以及合并症和同时使用的药物方面均无显著差异。对照组（1.24±0.96）和美金刚组（2.96±0.1）之间的NIHSS变化有显著差异，（p<0.0001）。我们的结果表明，在CTEE的标准治疗中添加美金刚可导致NIHSS显著降低，证实患者神经功能得到改善。
